메뉴 건너뛰기




Volumn 11, Issue 11, 2009, Pages 1216-1225

HE3235 inhibits growth of castration-resistant prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 5ALPHA ANDROSTAN 3ALPHA, 17BETA DIOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; HE 3235; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

EID: 70350736088     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09960     Document Type: Article
Times cited : (18)

References (22)
  • 3
    • 24744471465 scopus 로고    scopus 로고
    • Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy
    • DOI 10.1002/jcb.20460
    • Burnstein K (2005). Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95, 657-669. (Pubitemid 41420154)
    • (2005) Journal of Cellular Biochemistry , vol.95 , Issue.4 , pp. 657-669
    • Burnstein, K.L.1
  • 5
    • 4944246790 scopus 로고    scopus 로고
    • Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer
    • DOI 10.1677/erc.1.00525
    • Scher HI, Buchanan G, Gerald W, Butler LM, and Tilley WD (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11, 459-476. (Pubitemid 39331277)
    • (2004) Endocrine-Related Cancer , vol.11 , Issue.3 , pp. 459-476
    • Scher, H.I.1    Buchanan, G.2    Gerald, W.3    Butler, L.M.4    Tilley, W.D.5
  • 6
    • 29144508739 scopus 로고    scopus 로고
    • Secondary hormonal therapy for advanced prostate cancer
    • DOI 10.1016/S0022-5347(05)00034-0, PII S0022534705000340
    • Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, and Belldegrun AS (2006). Secondary hormonal therapy for advanced prostate cancer. J Urol 175, 27-34. (Pubitemid 41797079)
    • (2006) Journal of Urology , vol.175 , Issue.1 , pp. 27-34
    • Lam, J.S.1    Leppert, J.T.2    Vemulapalli, S.N.3    Shvarts, O.4    Belldegrun, A.S.5
  • 7
    • 27644452640 scopus 로고    scopus 로고
    • Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
    • Titus MA, Schell MJ, Lih FB, Tomer KB, and Mohler JL (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11, 4653-4657.
    • (2005) Clin Cancer Res , vol.11 , pp. 4653-4657
    • Titus, M.A.1    Schell, M.J.2    Lih, F.B.3    Tomer, K.B.4    Mohler, J.L.5
  • 10
    • 53749090666 scopus 로고    scopus 로고
    • Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven
    • Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. J Clin Oncol 26, 4563-4571.
    • (2008) J Clin Oncol , vol.26 , pp. 4563-4571
    • Attard, G.1    Reid, A.H.2    Yap, T.A.3    Raynaud, F.4    Dowsett, M.5    Settatree, S.6    Barrett, M.7    Parker, C.8    Martins, V.9    Folkerd, E.10
  • 11
    • 53349101498 scopus 로고    scopus 로고
    • Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β- hydroxy-17-(1H- benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
    • Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, and Brodie AM (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β- hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7, 2348-2357.
    • (2008) Mol Cancer Ther , vol.7 , pp. 2348-2357
    • Vasaitis, T.1    Belosay, A.2    Schayowitz, A.3    Khandelwal, A.4    Chopra, P.5    Gediya, L.K.6    Guo, Z.7    Fang, H.B.8    Njar, V.C.9    Brodie, A.M.10
  • 12
    • 63849108231 scopus 로고    scopus 로고
    • Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235)
    • Trauger R, Corey E, Bell D, White S, Garsd A, Stickney D, Reading C, and Frincke J (2009). Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235). Br J Cancer 100, 1068-1072.
    • (2009) Br J Cancer , vol.100 , pp. 1068-1072
    • Trauger, R.1    Corey, E.2    Bell, D.3    White, S.4    Garsd, A.5    Stickney, D.6    Reading, C.7    Frincke, J.8
  • 14
    • 0034234571 scopus 로고    scopus 로고
    • LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis
    • DOI 10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L
    • Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, and Chung LW (2000). LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103. (Pubitemid 30419183)
    • (2000) Prostate , vol.44 , Issue.2 , pp. 91-103
    • Thalmann, G.N.1    Sikes, R.A.2    Wu, T.T.3    Degeorges, A.4    Chang, S.-M.5    Ozen, M.6    Pathak, S.7    Chung, L.W.K.8
  • 15
    • 33749856315 scopus 로고    scopus 로고
    • Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes
    • DOI 10.1593/neo.06328
    • Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8, 862-878. (Pubitemid 44564842)
    • (2006) Neoplasia , vol.8 , Issue.10 , pp. 862-878
    • Coleman, I.M.1    Kiefer, J.A.2    Brown, L.G.3    Pitts, T.E.4    Nelson, P.S.5    Brubaker, K.D.6    Vessella, R.L.7    Corey, E.8
  • 16
    • 0036604237 scopus 로고    scopus 로고
    • Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells
    • DOI 10.1002/pros.10091
    • Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, and Vessella RL (2002). Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52, 20-33. (Pubitemid 34553189)
    • (2002) Prostate , vol.52 , Issue.1 , pp. 20-33
    • Corey, E.1    Quinn, J.E.2    Bladou, F.3    Brown, L.G.4    Roudier, M.P.5    Brown, J.M.6    Buhler, K.R.7    Vessella, R.L.8
  • 21
    • 34250901788 scopus 로고    scopus 로고
    • Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells
    • Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, and Morris JD (2007). Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 121, 520-527.
    • (2007) Int J Cancer , vol.121 , pp. 520-527
    • Carey, A.M.1    Pramanik, R.2    Nicholson, L.J.3    Dew, T.K.4    Martin, F.L.5    Muir, G.H.6    Morris, J.D.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.